Medical Necessity of Vedolizumab for Ulcerative Colitis

Guideline Support for Medical Necessity

The British Society of Gastroenterology conditionally recommends vedolizumab for induction and maintenance of remission in patients with moderate to severe ulcerative colitis, with moderate certainty evidence showing a small but meaningful benefit 1
The Toronto Consensus Guidelines provide a strong recommendation for continued vedolizumab maintenance therapy in patients who respond to induction, based on moderate-quality evidence 2

The pivotal GEMINI I trial demonstrated that vedolizumab maintenance therapy at 300mg every 8 weeks achieved clinical remission in 41.8% of patients at week 52, compared to only 15.9% with placebo 1, 2
No significant difference in efficacy exists between every 4-week and every 8-week dosing, establishing every 8 weeks as the appropriate standard maintenance interval 1, 2
Long-term safety data from 9 clinical trials involving 579 patients showed vedolizumab to be well tolerated with no new safety signals during extended treatment periods 2

The every 8-week dosing interval is the FDA-approved and guideline-recommended standard maintenance regimen for vedolizumab in ulcerative colitis 1, 2

Adverse event rates with vedolizumab are similar to placebo, with the most common adverse events being mild: headache, nausea, abdominal pain, fatigue, and nasopharyngitis 2
No cases of progressive multifocal leukoencephalopathy have been reported in approximately 3000 patients exposed to vedolizumab for a median of 18.8 months 2
Serious infections were not more common with vedolizumab than with placebo in clinical trials 2

Patients who demonstrate clinical response to vedolizumab induction therapy should continue maintenance therapy to preserve remission and prevent disease relapse 1, 2
Maintenance therapy aims to sustain corticosteroid-free clinical remission, achieve mucosal healing, and prevent disease complications—all of which are supported by vedolizumab continuation 1, 2

Stopping vedolizumab maintenance therapy in a responding patient without documented treatment failure or intolerable adverse effects contradicts evidence-based guidelines and increases risk of disease relapse 1, 2